Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Abstract Tumor treatment is still complicated in the field of medicine. Tumor immunotherapy has been the most interesting research field in cancer therapy. Application of chimeric antigen receptor T (CAR-T) cell therapy has recently achieved excellent clinical outcome in patients, especially those w...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-05-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12943-018-0840-y |
| _version_ | 1818900093180313600 |
|---|---|
| author | Yanyu Pang Xiaoyang Hou Chunsheng Yang Yanqun Liu Guan Jiang |
| author_facet | Yanyu Pang Xiaoyang Hou Chunsheng Yang Yanqun Liu Guan Jiang |
| author_sort | Yanyu Pang |
| collection | DOAJ |
| description | Abstract Tumor treatment is still complicated in the field of medicine. Tumor immunotherapy has been the most interesting research field in cancer therapy. Application of chimeric antigen receptor T (CAR-T) cell therapy has recently achieved excellent clinical outcome in patients, especially those with CD19-positive hematologic malignancies. This phenomenon has induced intense interest to develop CAR-T cell therapy for cancer, especially for solid tumors. However, the performance of CAR-T cell treatment in solid tumor is not as satisfactory as that in hematologic disease. Clinical studies on some neoplasms, such as glioblastoma, ovarian cancer, and cholangiocarcinoma, have achieved desirable outcome. This review describes the history and evolution of CAR-T, generalizes the structure and preparation of CAR-T, and summarizes the latest advances on CAR-T cell therapy in different tumor types. The last section presents the current challenges and prospects of CAR-T application to provide guidance for subsequent research. |
| first_indexed | 2024-12-19T19:58:22Z |
| format | Article |
| id | doaj.art-2e330acfcd884f5ea46d433c58be0894 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-12-19T19:58:22Z |
| publishDate | 2018-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-2e330acfcd884f5ea46d433c58be08942022-12-21T20:07:44ZengBMCMolecular Cancer1476-45982018-05-0117111010.1186/s12943-018-0840-yAdvances on chimeric antigen receptor-modified T-cell therapy for oncotherapyYanyu Pang0Xiaoyang Hou1Chunsheng Yang2Yanqun Liu3Guan Jiang4Department of Dermatology, Affiliated Hospital of Xuzhou Medical UniversityDepartment of Dermatology, Affiliated Hospital of Xuzhou Medical UniversityDepartment of Dermatology, Affiliated Huai’an Hospital of Xuzhou Medical University, the Second People’s Hospital of Huai’anDepartment of Dermatology, Affiliated Hospital of Xuzhou Medical UniversityDepartment of Dermatology, Affiliated Hospital of Xuzhou Medical UniversityAbstract Tumor treatment is still complicated in the field of medicine. Tumor immunotherapy has been the most interesting research field in cancer therapy. Application of chimeric antigen receptor T (CAR-T) cell therapy has recently achieved excellent clinical outcome in patients, especially those with CD19-positive hematologic malignancies. This phenomenon has induced intense interest to develop CAR-T cell therapy for cancer, especially for solid tumors. However, the performance of CAR-T cell treatment in solid tumor is not as satisfactory as that in hematologic disease. Clinical studies on some neoplasms, such as glioblastoma, ovarian cancer, and cholangiocarcinoma, have achieved desirable outcome. This review describes the history and evolution of CAR-T, generalizes the structure and preparation of CAR-T, and summarizes the latest advances on CAR-T cell therapy in different tumor types. The last section presents the current challenges and prospects of CAR-T application to provide guidance for subsequent research.http://link.springer.com/article/10.1186/s12943-018-0840-yChimeric antigen receptor T cellsHematological malignanciesAcute lymphoblastic leukemiaSolid tumorsCytokine release syndrome |
| spellingShingle | Yanyu Pang Xiaoyang Hou Chunsheng Yang Yanqun Liu Guan Jiang Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy Molecular Cancer Chimeric antigen receptor T cells Hematological malignancies Acute lymphoblastic leukemia Solid tumors Cytokine release syndrome |
| title | Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy |
| title_full | Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy |
| title_fullStr | Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy |
| title_full_unstemmed | Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy |
| title_short | Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy |
| title_sort | advances on chimeric antigen receptor modified t cell therapy for oncotherapy |
| topic | Chimeric antigen receptor T cells Hematological malignancies Acute lymphoblastic leukemia Solid tumors Cytokine release syndrome |
| url | http://link.springer.com/article/10.1186/s12943-018-0840-y |
| work_keys_str_mv | AT yanyupang advancesonchimericantigenreceptormodifiedtcelltherapyforoncotherapy AT xiaoyanghou advancesonchimericantigenreceptormodifiedtcelltherapyforoncotherapy AT chunshengyang advancesonchimericantigenreceptormodifiedtcelltherapyforoncotherapy AT yanqunliu advancesonchimericantigenreceptormodifiedtcelltherapyforoncotherapy AT guanjiang advancesonchimericantigenreceptormodifiedtcelltherapyforoncotherapy |